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RESEARCH

Open Access

A randomized trial of 7-day doripenem versus
10-day imipenem-cilastatin for ventilatorassociated pneumonia
Marin H Kollef1*, Jean Chastre2, Marc Clavel3, Marcos I Restrepo4, Bart Michiels5, Koné Kaniga6, Iolanda Cirillo6,
Holly Kimko6 and Rebecca Redman6

Abstract
Introduction: The aim of this study was to compare a 7-day course of doripenem to a 10-day course of
imipenem-cilastatin for ventilator-associated pneumonia (VAP) due to Gram-negative bacteria.
Methods: This was a prospective, double-blinded, randomized trial comparing a fixed 7-day course of doripenem
one gram as a four-hour infusion every eight hours with a fixed 10-day course of imipenem-cilastatin one gram as
a one-hour infusion every eight hours (April 2008 through June 2011).
Results: The study was stopped prematurely at the recommendation of the Independent Data Monitoring
Committee that was blinded to treatment arm assignment and performed a scheduled review of data which
showed signals that were close to the pre-specified stopping limits. The final analyses included 274 randomized
patients. The clinical cure rate at the end of therapy (EOT) in the microbiological intent-to-treat (MITT) population
was numerically lower for patients in the doripenem arm compared to the imipenem-cilastatin arm (45.6% versus
56.8%; 95% CI, -26.3% to 3.8%). Similarly, the clinical cure rate at EOT was numerically lower for patients with
Pseudomonas aeruginosa VAP, the most common Gram-negative pathogen, in the doripenem arm compared to
the imipenem-cilastatin arm (41.2% versus 60.0%; 95% CI, -57.2 to 19.5). All cause 28-day mortality in the MITT
group was numerically greater for patients in the doripenem arm compared to the imipenem-cilastatin arm (21.5%
versus 14.8%; 95% CI, -5.0 to 18.5) and for patients with P. aeruginosa VAP (35.3% versus 0.0%; 95% CI, 12.6 to 58.0).
Conclusions: Among patients with microbiologically confirmed late-onset VAP, a fixed 7-day course of doripenem
was found to have non-significant higher rates of clinical failure and mortality compared to a fixed 10-day course
of imipenem-cilastatin. Consideration should be given to treating patients with VAP for more than seven days to
optimize clinical outcome.
Trial Registration: ClinicalTrials.gov: NCT00589693

Introduction
Ventilator-associated pneumonia (VAP) is the most common infection identified in critically ill patients, often due
to high risk pathogens, such as Pseudomonas aeruginosa
and Acinetobacter baummannii, and accounts for most of
the antibiotic utilization within intensive care units (ICUs)
[1,2]. Several guidelines have been published giving
* Correspondence: mkollef@dom.wustl.edu
1
Division of Pulmonary and Critical Care Medicine, Washington University
School of Medicine, St. Louis, 660 South Euclid Avenue, Campus Box 8052,
St. Louis, MO 63110, USA
Full list of author information is available at the end of the article

recommendations for the treatment of VAP, including the
total duration of therapy [3,4]. Unfortunately, the evidence
supporting an optimal duration of antibiotic therapy for
VAP is limited and primarily based on the results of a single randomized trial [5]. A recent meta-analysis found that
for patients with nosocomial pneumonia not due to nonlactose fermenting Gram-negative bacteria (NLFGNB), a
short fixed-course (7 or 8 days) of antibiotic therapy may
be more appropriate than a prolonged course (10 to 15
days) in terms of reducing the subsequent emergence of
antibiotic-resistant pathogens [6]. However, the concern
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with using short durations of antibiotic therapy is treatment failure and potentially adverse outcomes.
Carbapenems are bactericidal against Gram-negative
pathogens that commonly cause VAP, including P. aeruginosa, A. baumannii and extended-spectrum beta-lactamase (ESBL) producing enteric bacteria, and are,
therefore, recommended for initial empiric therapy for
VAP in patients with late-onset disease or individuals with
risk factors for infection with multidrug-resistant (MDR)
pathogens [3,4,7]. Doripenem 500 mg was shown to be
non-inferior to comparator agents in two previous randomized controlled studies in patients with hospital-acquired
pneumonia, including VAP, when administered for 7 to 14
days, with the length of therapy guided by the patient’s
condition and at the discretion of the treating physicians
[8,9]. In addition, pharmacokinetic/pharmacodynamic
(PK/PD) modeling from data from other studies demonstrated that one gram doses infused over four hours could
target pathogens with higher minimum inhibitory concentrations (MICs) and provide a more sustained duration of
free drug concentrations above the MIC of most Gramnegative pathogens causing VAP (especially P. aeruginosa
and Acinetobacter spp.) than the 500 mg dose [10,11].
Therefore, we performed an investigation to compare the
administration of a higher 1 g dose of doripenem for a
fixed 7-day course to a fixed10-day course of imipenemcilastatin for the treatment of late-onset VAP. The rationale for the use of a 7-day course of doripenem was
guided by data from the prior doripenem nosocomial
pneumonia registration trials and a previous study demonstrating similar outcomes in patients with VAP treated
with 8 and 15 days of antibiotic therapy [5,8,9].
Doripenem is not approved for treatment of nosocomial
pneumonia, including VAP, in the United States (US) but
is approved for use in adults with these infections in the
European Union and other countries outside of the US.

Materials and methods
Study design overview

A randomized, double-blind, multicenter study was performed comparing the efficacy and safety of a fixed 7-day
regimen of doripenem to a fixed 10-day regimen of imipenem-cilastatin in patients with late-onset VAP, with
patients enrolled between 1 April 2008 and 17 May 2011.
Ventilated patients were stratified at the time of randomization based on age (≤65 years or >65 years), degree of
lung injury as measured by the ratio of the partial pressure
of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2
of ≤250 or >250), and geographic region (Western Europe,
North America, Australia; Central and South America; or
Eastern Europe and Asia). The institutional review board
at each site (see Acknowledgements) approved the protocol, and all patients or their authorized representatives
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provided written informed consent (NCT00589693). (See
Additional file 1 for complete Methods section).
Randomization and treatment regimens

In this double-blinded study patients were randomized
(1:1) to receive either a fixed 7-day course of doripenem
one gram as a four-hour infusion every eight hours or a
fixed 10-day course of imipenem-cilastatin one gram as a
one-hour infusion every eight hours. Treatment was randomized with use of a central interactive phone system.
Randomization was not stratified by study site. Patients
randomized to doripenem treatment received in parallel 7
days of active therapy and 10 days of placebo. Patients randomized to imipenem-cilastatin treatment received in parallel 10 days of active therapy and 7 days of placebo. All
patients received active study drug and placebo infusions
on Days 1 through 7. Patients randomized to imipenemcilastatin continued to receive active study drug on Days
8, 9 and 10 and patients randomized to doripenem
received placebo. A switch to oral antibacterial therapy
was not allowed. Adjunctive therapy was allowed at the
discretion of the treating physician with vancomycin
(1 gram every 12 hours) or linezolid (600 mg every 12
hours) directed at methicillin-resistant Staphylococcus aureus (MRSA) and amikacin (15 mg/kg once daily) for
patients at risk for infection with a carbapenem-resistant
Gram-negative pathogen.
Outcomes and follow-up

The intent-to-treat (ITT) population was defined as all
patients who received at least one dose of the study drug.
The microbiological ITT (MITT) population was the subset of the ITT population who had at least one Gramnegative pathogen identified on bronchoalveolar lavage
(BAL) or mini-BAL at a density >104 CFU/mL with an
imipenem MIC <8 μg/mL. Patients were included in the
MITT population if they had a second pathogen isolated
from BAL/mini-BAL at a density >104 CFU/mL with an
imipenem MIC >8 μg/mL. This was allowed to optimize
enrollment of patients with eligible Gram-negative pathogens and to allow inclusion of co-infection with MRSA.
However, patients who only grew pneumonia pathogens
with imipenem MICs >8 μg/mL, such as MRSA or Stenotrophomonas maltophilia, were excluded from the MITT
population.
Clinical assessments were performed at baseline and at
the end of therapy (EOT), defined as Day 10 for both
groups, or within 24 hours after the last dose of blinded
study drug therapy if discontinued early. Laboratory
assessments were performed at baseline, Day 7 and EOT.
Follow-up assessments were conducted 7 to 14 days and
28 to 35 days after EOT. The primary endpoint of this
study was clinical cure at EOT (Day 10) in the MITT

Kollef et al. Critical Care 2012, 16:R218
http://ccforum.com/content/16/6/R218

population. Secondary endpoints included 28-day allcause mortality in the MITT populations and clinical cure
in the subgroup having P. aeruginosa identified as a qualifying pathogen.
Clinical cure was defined as improvement or lack of
progression of baseline radiographic findings at EOT and
resolution of signs and symptoms of pneumonia at follow-up. Failure was defined as persistence or progression
of signs and symptoms or progression of radiological
signs of pneumonia at EOT; termination of study medications due to “lack of efficacy"; administration of any
systemically absorbed or aerosolized antibiotic for any
reason; death from any cause; an indeterminate response;
or relapsed infection at follow-up after termination of
study medications. Adverse events (AEs) including mortality, vital signs and laboratory parameters were also
evaluated.
Statistical analysis

The initial sample size calculation was based on assumptions from a previous Phase 3 doripenem pneumonia
study conducted in patients with VAP [9). Assuming a
clinical cure rate of 60% in both treatment arms and using
a non-inferiority margin of 15% and a one-tailed 2.5% significance level, a sample size of 168 per treatment arm
would have a power of 80% to establish non-inferiority. If
one further assumed that only 70% of the patients would
qualify for inclusion in the MITT analysis set, then the
sample size required would be 240 per treatment arm for
a total of 480 patients. Categorical data were expressed as
frequency distributions and the difference between groups
was assessed by using the normal approximation to the
difference between two binomial proportions. All confidence intervals were two-tailed and a P-value <0.05 represented statistical significance. No correction for multiple
comparisons was implemented. The P-values in the secondary and subgroup analyses are nominal in nature, and
not inferential.
Independent Data Monitoring Committee

An Independent Data Monitoring Committee (IDMC) was
established to evaluate data related to efficacy and safety at
predefined time points (see on-line supplement for IDMC
statistical monitoring guidelines). At their last meeting, the
IDMC reviewed available data from approximately half the
total number of patients targeted for enrollment and
recommended that the enrollment be terminated because
of inferior efficacy and higher mortality in one of the treatment arms. Therefore, the analyses were based on data
from the 274 subjects who had been randomized into the
study at the time enrollment was terminated. In addition,
five sites (three in Guatemala, one in Germany, one in the
United States) that enrolled a total of 41 patients were
deemed to be non-compliant with good clinical practices
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(GCP) prior to database lock and were excluded from the
primary analyses of efficacy and safety (Figure 1). However, to assess the robustness of the primary efficacy and
safety conclusions, sensitivity analyses were performed by
including patients from these five sites. These sensitivity
analyses support the primary efficacy and safety
conclusions.

Results
Patient disposition and characteristics

There were 274 randomized patients prior to stopping the
study. In addition to the 41 patients from the GCP noncompliant sites, 7 patients were excluded who never
received the study drug (1 patient was excluded for meeting both of these criteria). The ITT group comprised 227
patients (doripenem, n = 115; imipenem-cilastatin, n =
112) and the MITT group comprised 167 patients (doripenem, n = 79; imipenem-cilastatin, n = 88) (Figure 1).
Patient baseline characteristics were generally balanced
between treatment groups for the ITT and MITT populations although there were some differences between treatment groups suggesting subjects in the doripenem arm
may have more severe illness. The majority of patients
were male, white, <65 years of age (mean of 54.1 years in
the MITT population), had an Acute Physiology and
Chronic Health Evaluation (APACHE) II score >15, a clinical pulmonary infection score (CPIS) ≥6, PaO2/FiO2 <250,
a creatinine clearance >50 ml/min, received >72 hours of
prior antibiotic therapy, and enrolled from sites in Europe
(Tables 1 and 2). The most common reasons patients in
the MITT population were admitted to the hospital were
for surgery (38.9%), including neurologic surgery (17.4%),
a neurologic event (20.4%) and trauma (18.6%). A qualifying Gram-negative pathogen was isolated from 89.2% of
patients in the MITT population and more than half of
these patients had a second pathogen isolated from the
baseline BAL/mini-BAL at a density >104 CFU/mL.
The median duration of study drug therapy (including
placebo) was 9.7 days for each treatment arm in the MITT
population. The median duration of active study drug
therapy (excluding placebo) was 7.0 days in the doripenem
arm and 10.0 days in the imipenem-cilastatin arm for the
MITT population. Similar numbers of patients received
empiric adjunctive therapy with an aminoglycoside or an
anti-MRSA drug and less than 10% in both the ITT and
MITT groups continued adjunctive antibiotics beyond 72
hours after a carbapenem-resistant pathogen (defined as
imipenem MIC >8 μg/mL) was isolated (Tables 1 and 2).
Clinical and microbiologic response

The clinical cure rate at the EOT visit in patients in the
MITT group randomized to doripenem was lower than
the clinical cure rate in patients randomized to imipenem-cilastatin (45.6% versus 56.8%; 95% CI, -26.3% to
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Figure 1 Patients enrolled and analyzed. ITT, intention-to-treat; MITT, Microbiological intention-to-treat. *Prior to study termination the
Marketing Authorization Holder for the study identified five study sites (three in Guatemala, one in Germany, one in the United States),
following independent internal reviews and re-monitoring by a contract research organization (CRO), that were found not to have adhered to
the study protocols, or the study logs could not verify protocol adherence, and thus their data were excluded from the primary analyses.

3.8%). Thus, non-inferiority of a fixed 7-day treatment
regimen with doripenem compared to a fixed 10-day
treatment regimen of imipenem-cilastatin was not
demonstrated at the 15% margin. Response differences
of 10% to 15% favoring imipenem-cilastatin remained
present in most subgroups (Figure 2), especially among
male patients and those with supra-normal creatinine
clearance. However, the larger differences in cure rates
in patients with supra-normal creatinine clearance
appear to be driven by the unusually high cure rates
among subjects in the imipenem-cilastatin arm with
creatinine clearance >150 ml/min (71.4%) compared to
cure rates among those with creatinine clearance >80 to
<150 ml/min (51.4%) and >50 to <80 ml/min (50.0%).
The mean CPIS values for MITT patients in both
treatment arms for study Days 1 through 11 is shown in
Figure 3. CPIS scores were similar for patients in the
doripenem arm and the imipenem-cilastatin arm for the
first eight days of the study. However, the CPIS scores
separated after Day 8 with the doripenem arm scores
remaining stable while the imipenem-cilastatin arm
scores continued to decrease.
The distribution of qualifying Gram-negative pathogens
that were pre-defined as being of specific interest (P. aeruginosa, Acinetobacter spp., and Enterobacteriaceae) is
shown in Table 3. A larger proportion of patients in the
doripenem arm than the imipenem-cilastatin arm had

pneumonia due to P. aeruginosa (21.5% versus 11.4%) and
Acinetobacter spp. (19.0% versus 11.4%). The clinical cure
rate for the P. aeruginosa subgroup at EOT was numerically lower for subjects in the doripenem arm compared
to the imipenem-cilastatin arm (41.2% (7/17) versus 60.0%
(6/10); 95% CI, -57.2% to 19.5%). Cure rates were also
lower for patients in the doripenem arm infected with Acinetobacter spp. (40.0% (6/15) versus 50.0% (5/10); 95% CI:
-49.7% to 29.7%) and Enterobacteriaceae (53.5% (23/43)
versus 59.2% (29/49); 95% CI: -26.0% to 14.6%). Table 4
shows that the baseline characteristics for the P. aeruginosa subgroup were similar between treatment arms.
The number of patients with pathogens at each MIC
was too small to draw definitive conclusions regarding
clinical cure rate by infecting pathogen MIC; however, for
the NLFGNB P. aeruginosa and A. baumannii, cure rates
and mortality for patients in either treatment arm did not
appear to increase with increasing MIC of the study drug
received suggesting conditions other than MIC played a
role in outcome (see Additional file 1, Table S1).
Safety

In the ITT population, the most frequently reported
adverse events in both treatment groups were anemia
(21.7% doripenem, 22.3% imipenem-cilastatin); urinary
tract infection (13.0% doripenem, 14.3% imipenemcilastatin); decubitus ulcer (12.2% doripenem, 9.8%
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Table 1 Baseline demographics - ITT analysis set
Doripenem

Imipenem

Total

(N = 115)

(N = 112)

(N = 227)

N

115

112

227

Male

72 (62.6)

75 (67.0)

147 (64.8)

Female

43 (37.4)

37 (33.0)

80 (35.2)

N

115

112

227

Mean (SD)
Median

75.6 (16.95)
74.0

79.8 (19.07)
77.5

77.7 (18.11)
75.0

Range

(45;150)

(47; 170)

(45; 170)

N

114

110

224

Mean (SD)

169.5 (10.66)

171.3 (9.20)

170.3 (9.99)

Median

170.0

170.0

170.0

Range

(140; 193)

(150; 200)

(140; 200)

Age (Years)
N

115

112

227

Mean (SD)

57.5 (16.53)

54.6 (18.46)

56.1 (17.53)

Median

58.0

58.0

58.0

Range

(19; 89)

(18; 88)

(18; 89)

N

115

112

227

White

96 (83.5)

97 (86.6)

193 (85.0)

Black or African American
Asian

6 (5.2)
4 (3.5)

6 (5.4)
1 (0.9)

12 (5.3)
5 (2.2)

Other

9 (7.8)

8 (7.1)

17 (7.5)

N

115

112

227

Central and South America

24 (20.9)

24 (21.4)

48 (21.1)

Eastern Europe and Asia

34 (29.6)

33 (29.5)

67 (29.5)

Western Europe, North America, Australia

57 (49.6)

55 (49.1)

112 (49.3)

Sex, n (%)

Weight (kg)

Height (cm)

Race, n (%)

Region, n (%)

APACHE II score, n (%)
N
≤15

115

112

227

48 (41.7)

49 (43.8)

97 (42.7)

16 to 19

30 (26.1)

34 (30.4)

64 (28.2)

≥20

37 (32.2)

29 (25.9)

66 (29.1)

N

115

112

227

Missing

3 (2.6)

2 (1.8)

5 (2.2)

<6
6 to 7

8 (7.0)
64 (55.7)

5 (4.5)
64 (57.1)

13 (5.7)
128 (56.4)

8 to 9

30 (26.1)

34 (30.4)

64 (28.2)

>9

10 (8.7)

7 (6.3)

17 (7.5)

N

57

58

115

Mean (SD)

6.0 (2.70)

5.5 (2.39)

5.8 (2.55)

Median

6.0

5.0

5.0

(0; 14)

(2; 12)

(0; 14)

N

114

112

226

Mean (SD)

3.0 (2.72)

2.8 (2.45)

2.9 (2.59)

CPIS, n (%)

SOFA Score

Range
Charlson Comorbidity Index
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Table 1 Baseline demographics - ITT analysis set (Continued)
Median

3.0

3.0

3.0

Range

(0; 14)

(0; 9)

(0; 14)

115
67 (58.3)

112
61 (54.5)

227
128 (56.4)

48 (41.7)

51 (45.5)

99 (43.6)

N

115

112

227

No

109 (94.8)

107 (95.5)

216 (95.2)

Yes

6 (5.2)

5 (4.5)

11 (4.8)

115
23 (20.0)

112
34 (30.4)

227
57 (25.1)

PaO2/FiO2, n (%)
N
≤250
>250
Bacteremia, n (%)

Creatinine clearance, n (%)
N
Supra normal (≥150 ml/min)
Normal (≥80 to <150 ml/min)

46 (40.0)

44 (39.3)

90 (39.6)

Mild renal failure (>50 to <80 ml/min)

33 (28.7)

26 (23.2)

59 (26.0)

Moderate renal failure (>30 to ≤50 ml/min)

7 (6.1)

4 (3.6)

11 (4.8)

Severe renal failure (≤30 ml/min)

6 (5.2)

4 (3.6)

10 (4.4)

N

69

78

147

No
Yes

59 (85.5)
10 (14.5)

67 (85.9)
11 (14.1)

126 (85.7)
21 (14.3)

N

115

112

227

<24

28 (24.3)

35 (31.3)

63 (27.8)

≥24 to <48

10 (8.7)

10 (8.9)

20 (8.8)

≥48 to ≤72

9 (7.8)

5 (4.5)

14 (6.2)

68 (59.1)

62 (55.4)

130 (57.3)

115

112

227

75 (65.2)

79 (70.5)

154 (67.8)

32 (27.8)

25 (22.3)

57 (25.1)

8 (7.0)

8 (7.1)

16 (7.0)

N

40

33

73

No
Yes

19 (47.5)

20 (60.6)

39 (53.4)

≤72 Hrs

20 (50.0)

12 (36.4)

32 (43.8)

>72 Hrs

1 (2.5)

1 (3.0)

2 (2.7)

N

40

33

73

No

14 (35.0)

9 (27.3)

23 (31.5)

20 (50.0)
6 (15.0)

18 (54.5)
6 (18.2)

38 (52.1)
12 (16.4)

Failed antibiotic treatment for VAP, n (%)

Prior antibacterial therapy usage (hours), n (%)

>72
Adjunctive therapy, n (%)
N
No
Yes
≤72 Hrs
>72 Hrs
Adjunctive aminoglycoside, n (%)

Adjunctive vancomycin/linezolid, n (%)

Yes
≤72 hrs
>72 hrs

APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection Score; ITT, intention-to-treat; SOFA, Sequential Organ Failure
Assessment

imipenem-cilastatin); hypokalemia (10.4% doripenem,
10.7% imipenem-cilastatin); diarrhea (9.6% doripenem,
11.6% imipenem-cilastatin); and hypotension (9.6%
doripenem, 8.9% imipenem-cilastatin). Clinically

important adverse events (all-causality) are shown in
Additional file 1. Laboratory results were also comparable between the study arms (see Additional file 1,
Table S2).
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Table 2 Baseline demographics - MITT analysis set
Doripenem

Imipenem

Total

(N = 79)

(N = 88)

(N = 167)

Sex, n (%)
79

88

167

Male

N

48 (60.8)

61 (69.3)

109 (65.3)

Female

31 (39.2)

27 (30.7)

58 (34.7)

Weight (kg)
N
Mean (SD)
Median
Range

79

88

167

75.5 (17.85)
75.0

78.7 (15.66)
78.0

77.2 (16.75)
76.0

(45; 150)

(47; 143)

(45; 150)

Height (cm)
N
Mean (SD)

79

87

166

170.8 (9.76)

171.7 (8.73)

171.3 (9.22)

Median

170.0

170.0

170.0

Range

(148; 193)

(150; 190)

(148; 193)

Age (years)
N
Mean (SD)

79

88

167

54.9 (16.10)

53.4 (18.94)

54.1 (17.62)

Median

56.0

57.0

57.0

Range

(19; 89)

(18; 88)

(18; 89)

Race, n (%)
N

79

88

167

65 (82.3)

75 (85.2)

140 (83.8)

Black or African American
Asian

5 (6.3)
1 (1.3)

6 (6.8)
1 (1.1)

11 (6.6)
2 (1.2)

Other

8 (10.1)

6 (6.8)

14 (8.4)

White

Region, n (%)
79

88

167

Central and South America

N

20 (25.3)

19 (21.6)

39 (23.4)

Eastern Europe and Asia

24 (30.4)

27 (30.7)

51 (30.5)

Western Europe, North America, Australia

35 (44.3)

42 (47.7)

77 (46.1)

APACHE II score group, n (%)
N

79

88

167

≤15

34 (43.0)

42 (47.7)

76 (45.5)

16 to 19

24 (30.4)

21 (23.9)

45 (26.9)

≥20

21 (26.6)

25 (28.4)

46 (27.5)

CPIS, n (%)
79

88

167

Missing

N

2 (2.5)

1 (1.1)

3 (1.8)

<6
6 to 7

4 (5.1)
43 (54.4)

2 (2.3)
50 (56.8)

6 (3.6)
93 (55.7)

8 to 9

23 (29.1)

29 (33.0)

52 (31.1)

7 (8.9)

6 (6.8)

13 (7.8)

>9
SOFA score
N
Mean (SD)
Median
Range
Charlson Comorbidity Index
N
Mean (SD)

41

46

87

5.7 (2.53)

5.2 (2.24)

5.4 (2.38)

6.0

5.0

5.0

(0; 11)

(2; 12)

(0; 12)

79

88

167

2.4 (2.08)

2.8 (2.48)

2.6 (2.30)
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Table 2 Baseline demographics - MITT analysis set (Continued)
Median

3.0

2.0

3.0

Range

(0; 9)

(0; 9)

(0; 9)

79
50 (63.3)

88
51 (58.0)

167
101 (60.5)

29 (36.7)

37 (42.0)

66 (39.5)

PaO2/FiO2, n (%)
N
≤250
>250
Bacteremia, n (%)
N

79

88

167

No

73 (92.4)

84 (95.5)

157 (94.0)

Yes

6 (7.6)

4 (4.5)

10 (6.0)

N
Supra normal (≥150 ml/min)

79
18 (22.8)

88
28 (31.8)

167
46 (27.5)

Normal (≥80 to <150 ml/min)

31 (39.2)

37 (42.0)

68 (40.7)

Mild renal failure (>50 to <80 ml/min)

23 (29.1)

18 (20.5)

41 (24.6)

Moderate renal failure (>30 to ≤50 ml/min)

5 (6.3)

2 (2.3)

7 (4.2)

Severe renal failure (≤30 ml/min)

2 (2.5)

3 (3.4)

5 (3.0)

Creatinine Clearance, n (%)

Failed antibiotic treatment, n (%)
N
No
Yes

55

68

123

45 (81.8)
10 (18.2)

58 (85.3)
10 (14.7)

103 (83.7)
20 (16.3)

Prior antibacterial therapy usage (hours), n (%)
N
<24

79

88

167

19 (24.1)

29 (33.0)

48 (28.7)
16 (9.6)

≥24 to <48

8 (10.1)

8 (9.1)

≥48 to ≤72

6 (7.6)

3 (3.4)

9 (5.4)

46 (58.2)

48 (54.5)

94 (56.3)

>72
Adjunctive therapy, n (%)
N
No

79

88

167

49 (62.0)

68 (77.3)

117 (70.1)

23 (29.1)

15 (17.0)

38 (22.8)

7 (8.9)

5 (5.7)

12 (7.2)

Yes
≤72 Hrs
>72 Hrs
Adjunctive aminoglycoside, n (%)
N
No
Yes
≤72 hrs
>72 hrs

30

20

50

15 (50.0)

11 (55.0)

26 (52.0)

14 (46.7)

8 (40.0)

22 (44.0)

1 (3.3)

1 (5.0)

2 (4.0)

Adjunctive vancomycin/linezolid, n (%)
N

30

20

50

No

9 (30.0)

6 (30.0)

15 (30.0)

16 (53.3)
5 (16.7)

11 (55.0)
3 (15.0)

27 (54.0)
8 (16.0)

Yes
≤72 hrs
>72 hrs

APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection Score; MITT, microbiological intention-to -treat; SOFA, Sequential
Organ Failure Assessment

All-cause 28-day mortality in the MITT group was
numerically higher for patients in the doripenem arm
compared to the imipenem-cilastatin arm (21.5% (17/79)
doripenem, 14.8% (13/88) imipenem-cilastatin; 95% CI,

-5.0% to 18.5%) and greater for patients with P. aeruginosa VAP (35.3% (6/17) versus 0.0% (0/10); 95% CI,
12.6% to 58.0%). Similar trends but smaller mortality
differences were demonstrated for the sensitivity
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Figure 2 Clinical cure rates at end of treatment by subgroup with 95% confidence intervals.

analyses for the MITT group (20.7% (19/92) doripenem,
16.7% (17/102) imipenem-cilastatin; 95% CI, -7.0% to
15.0%). Kaplan-Meier estimates are presented graphically for 28-day all-cause mortality for the ITT and
MITT populations (see Additional file 1). Figure 4
demonstrates that the Kaplan-Meier curves for the P.
aeruginosa subgroup are statistically, significantly different over the treatment arms (nominal P-value = 0.040)
with an increased separation after completion of study
drug administration. Notably, no patient in the imipenem arm with P. aeruginosa VAP died. In contrast,

mortality rates for patients with Acinetobacter spp. VAP
were lower for patients treated with doripenem (13.3%
(2/15) versus 30.0% (3/10); 95% CI: -49.9% to 16.5%).
Pharmacokinetics

The concentration data collected from 43 subjects treated with doripenem (between study Days 2 and 3) were
within the range of historical data in previously studied
critically ill patients administered doripenem 1 g for a
four-hour infusion. This data were utilized in a population PK/PD analysis along with data from subjects with
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Figure 3 Mean Clinical Pulmonary Infection Scores (CPIS) for the MITT treatment groups during antibiotic therapy. Error bars displayed
are based on the 95% confidence interval around the means. As there is significant dropout over time, as can be seen by the available sample
sizes at the bottom of the figure, the results have to be interpreted with caution. Nevertheless, the curves suggest that the patients’
improvement is similar for the two treatment arms up to Day 8 (the last day of active doripenem treatment), where after the decreasing trend is
continued for the subjects in the Imipenem-cilastatin arm (who receive active treatment up to Day 11), but remains stable for subjects in the
doripenem arm (who receive only placebo from Day 9 up to Day 11).

VAP from previously conducted studies (manuscript
under preparation). Higher volumes of distribution were
observed in this study population, likely attributable to
high peripheral fluid volumes and the VAP disease state.
Despite this, doripenem levels were maintained at levels
sufficient to target pathogens isolated from subjects in
this study.

Discussion
The main reasons to consider the use of shorter courses
of antibiotic therapy for VAP are to minimize antibioticrelated complications and to prevent the emergence of
antibiotic resistance. However, we demonstrated that
among patients with microbiologically confirmed VAP, a
fixed 7-day course of doripenem (one gram as a fourhour infusion every eight hours) had non-significant
higher rates of clinical failure and mortality compared to
a fixed 10-day course of imipenem-cilastatin (one gram
as a one-hour infusion every eight hours). Moreover,

patients with VAP attributed to P. aeruginosa had a statistically greater risk of 28-day all-cause mortality when
treated with doripenem compared to imipenem-cilastatin
with an increased separation in the survival curves after
completion of study drug administration. This occurred
despite the use of prolonged infusions of doripenem
aimed at optimizing antibiotic concentration target
attainment above the MIC of bacterial pathogens during
the dosing interval suggesting that the shorter course of
doripenem administration played a role in this survival
difference [12,13].
Our findings are in contrast to some earlier studies
suggesting that shorter courses of antibiotic therapy for
VAP are safe and efficacious compared to longer treatment courses. Ibrahim et al. showed that implementation of a clinical guideline for the treatment of VAP was
associated with greater administration of appropriate
initial antimicrobial treatment [14]. The duration of
antimicrobial treatment was also statistically shorter
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Table 3 Distribution of baseline qualifying Gram-negative pathogens

Specific Gram-negative Pathogens

Doripenem

Imipenem

Total

(N = 79)
n (%)

(N = 88)
n (%)

(N = 167)
n (%)

65 (82.3)

62 (70.5)

127 (76.0)

Pseudomonas aeruginosa

17 (21.5)

10 (11.4)

27 (16.2)

Monomicrobial*

8 (10.1)

6 (6.8)

14 (8.4)

Polymicrobial**

9 (11.4)

4 (4.5)

13 (7.8)

Acinetobacter spp.

15 (19.0)

10 (11.4)

25 (15.0)

Monomicrobial*
Polymicrobial**

3 (3.8)
12 (15.2)

4 (4.5)
6 (6.8)

7 (4.2)
18 (10.8)

43 (54.4)

49 (55.7)

92 (55.1)

14 (17.7)

14 (15.9)

28 (16.8)

1 (1.3)

0

1 (0.6)

0

1 (1.1)

1 (0.6)

Enterobacter cloacae

4 (5.1)

3 (3.4)

7 (4.2)

Escherichia coli

1 (1.3)

2 (2.3)

3 (1.8)

Klebsiella pneumoniae
Pantoea agglomerans

5 (6.3)
1 (1.3)

4 (4.5)
0

9 (5.4)
1 (0.6)

Proteus mirabilis

1 (1.3)

2 (2.3)

3 (1.8)

Serratia marcescens

1 (1.3)

2 (2.3)

3 (1.8)

29 (36.7)

35 (39.8)

64 (38.3)

Citrobacter freundii

0

3 (3.4)

3 (1.8)

Enterobacter aerogenes

0

2 (2.3)

2 (1.2)

Enterobacter asburiae

1 (1.3)

0

1 (0.6)

Enterobacter cloacae
Enterobacter spp. (Not Speciated)

4 (5.1)
1 (1.3)

2 (2.3)
0

6 (3.6)
1 (0.6)

Escherichia coli

5 (6.3)

12 (13.6)

17 (10.2)

Klebsiella oxytoca

1 (1.3)

1 (1.1)

2 (1.2)

14 (17.7)

16 (18.2)

30 (18.0)

3 (3.8)

3 (3.4)

6 (3.6)

1 (1.3)

1 (1.1)

2 (1.2)

0

1 (1.1)

1 (0.6)

3 (3.8)
7 (8.9)

3 (3.4)
4 (4.5)

6 (3.6)
11 (6.6)

Pseudomonas aeruginosa

2 (2.5)

1 (1.1)

3 (1.8)

Polymicrobial**

2 (2.5)

1 (1.1)

3 (1.8)

2 (2.5)

1 (1.1)

3 (1.8)

2 (2.5)

1 (1.1)

3 (1.8)

4 (5.1)

2 (2.3)

6 (3.6)

4 (5.1)

2 (2.3)

6 (3.6)

Enterobacteriaceae
Monomicrobial*
Citrobacter koseri
Enterobacter aerogenes

Polymicrobial**

Klebsiella pneumoniae
Proteus mirabilis
Proteus vulgaris
Providencia spp. (Not Speciated)
Serratia marcescens
Pneumonia with MRS

Acinetobacter spp.
Polymicrobial**
Enterobacteriaceae
Polymicrobial**

*: Monomicrobial pneumonia means a single qualifying pneumonia pathogen was isolated and no other pneumonia pathogen was isolated. **: Polymicrobial
pneumonia means at least one qualifying pneumonia pathogen was isolated and at least one other pneumonia pathogen was isolated. MRS, methicillin-resistant
Staphylococcus

with use of the guideline (8.6 ± 5.1 days versus 14.8 ±
8.1 days, P < 0.001) and second episodes of VAP
occurred statistically less often. In a subsequent study
the same group of investigators found that an antibiotic
discontinuation policy for clinically suspected VAP,
overseen by clinical pharmacists who were part of the
ICU team, could also significantly reduce the duration
of antibiotic therapy compared to therapy determined
by the treating physician teams (6.0 + 4.9 days versus

8.0 ± 5.6 days, P = 0.001) [15]. Secondary outcomes
including relapse of VAP, hospital mortality, and lengths
of stay were similar between groups, although the number of infections attributed to NLFGNB was small. Several groups have also employed prediction tools like
CPIS and the biomarker procalcitonin to successfully
reduce the duration of antimicrobial therapy in patients
with VAP without adversely influencing patient outcomes [16-18].
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Table 4 Baseline clinical characteristics - P.
Doripenem

Imipenem

Total

(N = 17)

(N = 10)

(N = 27)

Sex, n (%)
17

10

27

Male

N

13 (76.5)

7 (70.0)

20 (74.1)

Female

4 (23.5)

3 (30.0)

7 (25.9)

Weight (kg)
N
Mean (SD)
Median
Range

17

10

27

74.0 (17.85)
75.0

68.3 (12.12)
64.0

71.9 (15.96)
72.7

(45; 110)

(52; 90)

(45; 110)

Height (cm)
N
Mean (SD)

17

10

27

172.0 (10.11)

170.8 (7.74)

171.6 (9.17)

Median

170.0

171.0

170.0

Range

(156; 190)

(159; 180)

(156; 190)

Age (Years)
N
Mean (SD)

17

10

27

57.5 (15.58)

50.9 (20.32)

55.1 (17.40)

Median

57.0

53.5

57.0

Range

(33; 89)

(25; 77)

(25; 89)

Race, n (%)
N
White
Black or African American
Asian

17

10

27

16 (94.1)

7 (70.0)

23 (85.2)

1 (5.9)
0

2 (20.0)
1 (10.0)

3 (11.1)
1 (3.7)

Region, n (%)
N
Central and South America

17

10

27

5 (29.4)

3 (30.0)

8 (29.6)

Eastern Europe and Asia

5 (29.4)

4 (40.0)

9 (33.3)

Western Europe, North America, Australia

7 (41.2)

3 (30.0)

10 (37.0)

17
6 (35.3)

10
3 (30.0)

27
9 (33.3)

APACHE II score group, n (%)
N
≤15
16 to 19

5 (29.4)

3 (30.0)

8 (29.6)

≥20

6 (35.3)

4 (40.0)

10 (37.0)

CPIS, n (%)
N

17

10

27

<6

0

1 (10.0)

1 (3.7)

6 to 7

10 (58.8)

8 (80.0)

18 (66.7)

8 to 9
>9

5 (29.4)
2 (11.8)

1 (10.0)
0

6 (22.2)
2 (7.4)

SOFA score
N
Mean (SD)

10

4

14

5.4 (3.10)

4.0 (1.41)

5.0 (2.75)

Median

4.0

4.5

4.0

Range

(1; 10)

(2; 5)

(1; 10)

17
3.0 (2.26)

10
2.5 (1.96)

27
2.8 (2.13)

Charlson Comorbidity Index
N
Mean (SD)
Median

3.0

3.0

3.0

Range

(0; 9)

(0; 5)

(0; 9)
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Table 4 Baseline clinical characteristics - P. (Continued)
PaO2/FiO2, n (%)
N
≤250
>250
Bacteremia, n (%)

17

10

27

10 (58.8)

5 (50.0)

15 (55.6)

7 (41.2)

5 (50.0)

12 (44.4)

N

17

10

27

No

16 (94.1)

10 (100)

26 (96.3)

Yes

1 (5.9)

0

1 (3.7)

Creatinine clearance, n (%)
N

17

10

27

Supra normal(≥150 ml/min)

5 (29.4)

4 (40.0)

9 (33.3)

Normal (≥80 to <150 ml/min)
Mild renal failure (>50 to <80 ml/min)

5 (29.4)
4 (23.5)

2 (20.0)
3 (30.0)

7 (25.9)
7 (25.9)

Moderate renal failure (>30 to ≤50 ml/min)

2 (11.8)

1 (10.0)

3 (11.1)

Severe renal failure (≤30 ml/min)

1 (5.9)

0

1 (3.7)

Failed antibiotic treatment, n (%)
N

11

8

19

No

8 (72.7)

6 (75.0)

14 (73.7)

Yes

3 (27.3)

2 (25.0)

5 (26.3)

Prior antibacterial therapy usage (hours), n (%)
N

17

10

27

<24

4 (23.5)

0

4 (14.8)

≥24 to <48

2 (11.8)

1 (10.0)

3 (11.1)

≥48 to ≤72

1 (5.9)

0

1 (3.7)

10 (58.8)

9 (90.0)

19 (70.4)

>72
Adjunctive therapy, n (%)
N
No
Yes
≤72 hrs
>72 hrs

17

10

27

7 (41.2)

6 (60.0)

13 (48.1)

8 (47.1)

3 (30.0)

11 (40.7)

2 (11.8)

1 (10.0)

3 (11.1)

Adjunctive aminoglycoside, n (%)
N

10

4

14

No

4 (40.0)

2 (50.0)

6 (42.9)

5 (50.0)
1 (10.0)

2 (50.0)
0

7 (50.0)
1 (7.1)

Yes
≤72 hrs
>72 hrs
Adjunctive vancomycin/linezolid, n (%)
N

10

4

14

No

5 (50.0)

1 (25.0)

6 (42.9)

Yes
≤72 hrs

4 (40.0)

2 (50.0)

6 (42.9)

>72 hrs

1 (10.0)

1 (25.0)

2 (14.3)

aeruginosa analysis set APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection Score; SOFA, Sequential Organ Failure
Assessment

However, a number of studies suggest that shorter
courses of antibiotic therapy for VAP may potentially be
less favorable in some circumstances, especially for
treatment of infections attributed to NLFGNB. Chastre
et al. showed that among patients with VAP, all of
whom received appropriate initial empiric antibiotic

therapy, comparable clinical effectiveness and outcomes
were obtained with 8- and 15-day treatment regimens
[5]. Yet, patients with VAP caused by NLFGNB, including P. aeruginosa, receiving 8 days of treatment had a
higher pulmonary infection recurrence rate compared
with those receiving 15 days of treatment (40.6% versus
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Figure 4 Kaplan-Meier curves for the P. aeruginosa subgroup. (P = 0.040, Log-Rank Test).

25.4%; 95% CI, 3.9% to 26.6%). Hedrick et al. retrospectively evaluated 154 patients with VAP attributed to
NLFGNB where 27 patients were treated with three to
eight days (mean 6.4 + 0.3 days) of antibiotics and 127
received nine or more days (mean 17.1 + 0.7 days) of
therapy [19]. Although not statistically different, the
mortality rate was higher for patients receiving the
shorter treatment courses (22% versus 14%; P = 0.38).
Other investigators have demonstrated that longer
courses of antibiotic therapy (10 to 14 days) are typically
needed to successfully treat VAP attributed to MDR
Gram-negative bacteria, often due to the presence of
initial inappropriate antibiotic treatment [20,21].
Several potential explanations may have accounted for
our findings. The importance of adequate antimicrobial
dosing as a determinant of outcome has been demonstrated in several randomized controlled trials performed in critically ill patients with nosocomial
pneumonia [22-24]. Potentially, inadequately dosed antibiotics (ceftobiprole and tigecycline) were associated
with statistically greater treatment failures and mortality
compared to more optimally dosed comparators. Additionally, the results from two recent meta-analyses
examining prolonged infusion of b-lactam antibiotics
found that continuous infusion of b-lactam antibiotics
led to the same clinical results as similar or higher
dosed intermittent infusion antibiotic therapy [25,26].
However, in one of these meta-analyses, a trend towards
benefit among patients receiving intermittent infusion
antibiotics possibly explained by the use of higher antibiotic doses was observed [26]. The findings from a
recent study examining epithelial lining fluid (ELF) concentrations of doripenem in normal volunteers reported

the area under the curve ELF to plasma ratios was comparable to other carbapenems and supports further the
use of the 1 g dose versus a 500 mg dose administered
as a four-hour infusion to achieve higher doripenem
levels in the ELF [27].
A population PK analysis to characterize the PK of
doripenem in patients with VAP using data from subjects treated with doripenem from this study and
patients with VAP from previous studies showed good
PK coverage above MICs in this study, including the
subjects with supranormal creatinine clearance. In addition, the population PK/PD analysis demonstrated no
association between clinical outcomes and the infecting
pathogen MICs within the PK dataset from this study.
Plasma levels of doripenem were collected between
study Days 2 and 3 so the ability to determine these
doripenem exposure-response relationships closer to the
time that the study endpoint was assessed was limited.
However, notably, for subjects in both treatment arms,
cure rates and mortality did not appear to increase with
increasing MIC of the pathogens, suggesting conditions
other than MIC and antibiotic dosing played a role in
outcome. Furthermore, the mean distribution of CPIS
values during antibiotic treatment for the first seven
days of the study was similar for the two treatment
groups (Figure 3), only separating after completion of
therapy in the doripenem arm. This finding also suggests that the duration of antibiotic therapy and not the
antibiotics themselves contributed to the observed differences in outcomes.
Another potential explanation for our findings is that
achievement of the targeted antibiotic concentration
goals took longer with the use of the prolonged infusion
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compared to the shorter infusions of the time-dependent
carbapenems [28,29]. This could result in a delay in
clearance of the infection that could adversely influence
outcomes. The authors of a recent systematic review
describing the pharmacokinetics of b-lactam antibiotics
in the critically ill found that b-lactam antibiotic half-life
and time above the MIC were virtually unpredictable,
especially in those with normal renal function [30].
Moreover, two recent studies found that creatinine clearance appears to be an important predictor of sub-therapeutic b-lactam concentrations in critically ill patients
[31,32]. Administration of a loading dose of doripenem
might have improved concentration target attainment
potentially allowing for a shorter course of effective therapy, even in the setting of increased drug clearance
[30,32].
This study has several important limitations. First, clinical outcomes were assessed within 24 hours after administration of the last dose of blinded study drug. The
timing of this visit provided three days for patients in the
doripenem arm but less than 24 hours in the imipenemcilastatin arm to relapse. Had the clinical outcome assessment been postponed to a few days later, additional
relapses may have been observed in the imipenem-cilastatin arm. Second, premature closure of the study limited
the number of patients in the MITT group and pathogen-specific subgroups. Third, there were a large number
of study sites located in many countries which likely have
different treatment practices, introducing additional
variability. Fourth, enrollment occurred over the course
of three years and we cannot exclude temporal changes
in supportive care or other practices also having introduced additional variability. Fifth, allowing pathogens
with MICs greater than 8 μg/mL may have influenced
our results, especially for the shorter course of therapy.
Sixth, there were numerically more cases of VAP attributed to P. aeruginosa, A. baumannii and MRSA in the
doripenem arm compared to the imipenem-cilastatin
arm and other imbalances in baseline characteristics
between treatment groups which may have contributed
to the study findings. Lastly, there may be additional
imbalances between the two study groups that could
have increased the severity of VAP (for example, corticosteroid therapy, chronic obstructive pulmonary disease) that were not included in our analysis.

Conclusions
In summary, we demonstrated that a fixed 7-day course
of doripenem was found to have non-significant higher
rates of clinical failure and mortality compared to a fixed
10-day course of imipenem-cilastatin and a statistically
greater mortality for the subgroup of VAP attributed to
P. aeruginosa. Given the increasing prevalence of VAP
caused by MDR Gram-negative bacteria, it is imperative
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that optimal antimicrobial treatment strategies be
employed to optimize efficacy while minimizing the
emergence of further antibiotic resistance [33]. In countries where doripenem 500 mg one-hour and four-hour
infusions are approved to treat adults with nosocomial
pneumonia, including VAP, the usual treatment duration
is 7 to 14 days and should be guided by the severity of illness, infecting pathogen and the patients’ clinical
response with consideration given to treating patients
with VAP for more than 7 days to optimize clinical outcome. Moreover, the European Medicines Agency (EMA)
has recently recommended that doripenem 1 g doses
administered every eight hours as four-hour infusions be
considered in patients with augmented renal clearance
(particularly those with creatinine clearance ≥150 ml/
min) and/or in infections due to non-fermenting Gramnegative pathogens, such as P. aeruginosa and Acinetobacter spp. Moreover, the EMA highlighted that the
usual treatment duration for patients with nosocomial
pneumonia, including VAP, is 10 to 14 days and often in
the upper range for patients infected with NLFGNB [34].

Key messages
• A fixed 7-day course of doripenem was found to
have non-significant higher rates of clinical failure
and mortality compared to a fixed 10-day course of
imipenem-cilastatin for the treatment of VAP.
• VAP due to NLFGNB should be treated with antibiotic courses that are longer than seven days.
• The use of prolonged infusion antibiotic therapy
for VAP needs additional study to determine its relative efficacy compared to standard therapy.
Additional material
Additional file 1: A randomized trial of 7-day doripenem versus 10day imipenem-cilastatin for ventilator-associated pneumonia online supplement. Provides additional methods section, results and the
IDMC charter.
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multidrug-resistant; MIC: minimum inhibitory concentration; MITT:
microbiological intent-to-treat; MRSA: methicillin-resistant Staphylococcus
aureus; NLFGNB: non-lactose fermenting Gram-negative bacteria; PaO2:
partial pressure of arterial oxygen; PD: pharmacodynamic; PK:
pharmacokinetic; VAP: ventilator-associated pneumonia
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